



(51) International Patent Classification:

C07K 14/705 (2006.01) A61K 39/00 (2006.01)
C07K 14/16 (2006.01) A61K 38/00 (2006.01)
C07K 16/18 (2006.01) A61P 35/00 (2006.01)
C07K 16/30 (2006.01) A61P 37/00 (2006.01)
C12N 9/48 (2006.01) C07K 14/73 (2006.01)

(21) International Application Number:

PCT/IB2021/000358

(22) International Filing Date:

27 May 2021 (27.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/030,653 27 May 2020 (27.05.2020) US

(71) Applicants: **ANTION BIOSCIENCES SA** [CH/CH]; Rue Maurice 3, CH-124 Geneva (CH). **GENEVA UNIVERSITY HOSPITALS** [CH/CH]; Rue Gabrielle-Perret-Gentil 4, CH-1205 Geneva (CH). **UNIVERSITY OF GENEVA** [CH/CH]; 24, Rue Du General Dufour, CH-1211 Geneva

(CH), **UNIVERSITY OF ZURICH** [CH/CH]; Rämistrasse 71, CH-8006 Zurich (CH).

(72) Inventors: **ALESSANDRINI, Marco**; C/o University of Geneva, 24, Rue Du General Dufour, CH-1211 Geneva (CH). **KRAUSE, Karl-heinz**; C/o University of Geneva Medical School, 1, Rue Michael-Servet, Room F07.3365, 7th Flr, CH-1211 Geneva (CH). **MYBURGH, Renier**; C/o University of Zurich, Rämistrasse 71, CH-8006 Zurich (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: ADAPTER MOLECULES TO RE-DIRECT CAR T CELLS TO AN ANTIGEN OF INTEREST




FIG. 1C

(57) Abstract: Chimeric antigen receptor (CAR) bridging protein are provided comprising a CAR-binding domain linked to an antigen-binding domain, which can be used to re-direct the targeting of CAR-T cells. The bridging protein may comprise an antigen-binding domain that targets any antigen of interest, such as, for example, a tumor antigen or viral antigen. Also provided are methods of using the bridging proteins in combination with CAR-T cells to treat a disease, such as, for example, a cancer or an infectious disease.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*